

5 October 2022
EFPIA Japan

Takafumi Horii appointed new Vice Chair of EFPIA Japan

TOKYO – 5 October 2022 – European Federation of Pharmaceutical Industries and Associations Japan (EFPIA Japan) announced today that Takafumi Horii (President and Representative Director, AstraZeneca) has been appointed the new Vice Chair of EFPIA Japan effective 30 September, with terms until March 2023. This appointment is associated with the resignation of Yoshiaki Aono.

In addition, Shashank Deshpande (Representative Director, Chairman and President, Nippon Boehringer Ingelheim Co., Ltd.), Kasper Bødker Mejlvang (President and Representative Director, Novo Nordisk Pharma Ltd.) and Takafumi Horii have also been appointed new Board of Directors in the extraordinary general assembly meeting held on 15 September.

Together with Leo Lee (Novartis Pharma K.K.) who continues to serve in his position of Vice Chair, Takafumi Horii will support Takahiko Iwaya (Sanofi K.K.), the Chair of EFPIA Japan.

“The unsettling world situation underscores the need to build a more efficient, flexible and sustainable healthcare system that can adapt to a volatile and uncertain future as well as the speed of innovation. EFPIA Japan remains committed to contributing its expertise and knowledge to debates with stakeholders for finding solutions”, says Takafumi Horii upon the appointment.

EFPIA Japan Board Members as of 30 September 2022

Chair	Takahiko Iwaya	(Sanofi K.K.)	
Vice Chairs	Leo Lee	(Novartis Pharma K.K.)	
	Takafumi Horii	(AstraZeneca K.K.)	New
Board of Directors	Paul Lirette	(GlaxoSmithKline K.K.)	
	Julio Triana	(Bayer Yakuhin, Ltd.)	
	Shuhei Sekiguchi	(Janssen Pharmaceutical K.K.)	
	Kanako Kikuchi	(UCB Japan Co., Ltd.)	
	Shashank Deshpande	(Nippon Boehringer Ingelheim Co., Ltd.)	New
	Kasper Bødker Mejlvang	(Novo Nordisk Pharma Ltd.)	New
	Alexandre De Muralt	(Merck Biopharma Co., Ltd.)	
Director General	Takeo Morooka		



European Federation of Pharmaceutical
Industries and Associations

About EFPIA Japan (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceutical companies operating in Japan. In 2021, combined sales from the member companies accounted for roughly 26% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations)

(<https://www.efpia.eu/>)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 38 leading pharmaceutical companies and a growing number of small and medium-sized enterprises (SMEs), EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

Contact:

Yuko Kidoguchi

EFPIA Japan Communications Committee

1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268

Bayer Holding Ltd.

Tel: 03-6266-7757

Email: yuko.kidoguchi@bayer.com



President & Representative Director AstraZeneca K.K.

Takafumi Horii (Taka) is President & Representative Director of AstraZeneca K.K. and leads the business in Japan with 3,400 employees across Commercial, R&D and Operations.

EXPERIENCE

Prior to his role at AstraZeneca K.K., Taka served as Senior Vice President, Head of Japan Oncology Business Unit and a member of the Global Oncology Leadership Team, as well as being part of the Japan Country Committee at Takeda Pharmaceutical Company.

Previously, Taka held various leadership roles at Takeda across the world, including VP & Area Head of the Near-east, Middle-east and Africa covering 21 countries in the region, President & General Manager in Taiwan, VP & Head of Strategy of Emerging Market, and Head of Strategy for China.

Externally, Taka served as an executive committee member at the PhRMA in the Middle East and Africa when based in Dubai, as a standing board member and chairperson of the market access committee at the IRPMA (International Research-Based Pharmaceutical Manufacturers) and a vice-chairperson of the Pharmaceutical & Medical Committee at the JCCI (The Japan Chamber of Commerce and industry), demonstrating leadership in the industry to improve healthcare systems across countries, as well as improving access to medicine for patients.

Taka started his career at the global HQ, Canon Inc. After that, he joined a US-based IT start-up company to launch their business in Japan where he led a consulting delivery team, providing consulting services to major Japanese and multinational clients in pharma and non-pharma industries. Throughout his career, Taka has consistently taken on bigger responsibilities, as well as expanding his leadership experience through his international assignments in Dubai, Taiwan, Shanghai and Singapore.

AWARDS

“Top Employer in Middle East as a Regional Award” as a recognition of a holistic HR framework to empower Country Managers and HR Business partners.

“Top 100 Healthcare Leader Award” by IFAH as a recognition of contribution in emerging markets including improving access to medicine for patients.

EDUCATION

MBA, Darden Graduate School of Business, University of Virginia, the USA.